交易 Monte Rosa Therapeutics Inc - GLUE 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.06
• 长仓隔夜仓息调整: -0.02162%
• 短仓隔夜仓息调整: -0.00060%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 19.11
• 开仓: 19.08
• 1 年变化: 96.09%
• 日区间: 18.39 - 19.29

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body''s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn''s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.